Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor GPR139
Research output: Contribution to journal › Journal article › peer-review
Standard
Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor GPR139. / Shehata, Mohamed A; Jensen, Anne Cathrine Nøhr; Lissa, Delphine; Bisig, Christoph; Isberg, Vignir; Andersen, Kirsten B; Harpsøe, Kasper; Björkling, Fredrik; Bräuner-Osborne, Hans; Gloriam, David E.
In: Scientific Reports, Vol. 6, 36681, 10.11.2016, p. 1-13.Research output: Contribution to journal › Journal article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor GPR139
AU - Shehata, Mohamed A
AU - Jensen, Anne Cathrine Nøhr
AU - Lissa, Delphine
AU - Bisig, Christoph
AU - Isberg, Vignir
AU - Andersen, Kirsten B
AU - Harpsøe, Kasper
AU - Björkling, Fredrik
AU - Bräuner-Osborne, Hans
AU - Gloriam, David E
PY - 2016/11/10
Y1 - 2016/11/10
N2 - GPR139 is an orphan class A G protein-coupled receptor found mainly in the central nervous system. It has its highest expression levels in the hypothalamus and striatum, regions regulating metabolism and locomotion, respectively, and has therefore been suggested as a potential target for obesity and Parkinson's disease. The two aromatic amino acids L-Trp and L-Phe have been proposed as putative endogenous agonists, and three structurally related benzohydrazide, glycine benzamide, and benzotriazine surrogate agonist series have been published. Herein, we assayed 158 new analogues selected from a pharmacophore model, and identified 12 new GPR139 agonists, containing previously untested bioisosteres. Furthermore, we present the first combined structure-activity relationships, and a refined pharmacophore model to serve as a rationale for future ligand identification and optimization.
AB - GPR139 is an orphan class A G protein-coupled receptor found mainly in the central nervous system. It has its highest expression levels in the hypothalamus and striatum, regions regulating metabolism and locomotion, respectively, and has therefore been suggested as a potential target for obesity and Parkinson's disease. The two aromatic amino acids L-Trp and L-Phe have been proposed as putative endogenous agonists, and three structurally related benzohydrazide, glycine benzamide, and benzotriazine surrogate agonist series have been published. Herein, we assayed 158 new analogues selected from a pharmacophore model, and identified 12 new GPR139 agonists, containing previously untested bioisosteres. Furthermore, we present the first combined structure-activity relationships, and a refined pharmacophore model to serve as a rationale for future ligand identification and optimization.
U2 - 10.1038/srep36681
DO - 10.1038/srep36681
M3 - Journal article
C2 - 27830715
VL - 6
SP - 1
EP - 13
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
M1 - 36681
ER -
ID: 168780540